HC Wainwright & Co. reiterated coverage on I-MAB with a new price target

9/1/21 6:14:32 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

HC Wainwright & Co. reiterated coverage of I-MAB with a rating of Buy and set a new price target of $95.00 from $75.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$IMAB

Date	Price Target	Rating	Analyst
12/9/2021	$96.00	Buy	Siebert Williams Shank
11/1/2021	$83.00 → $85.00	Buy	Needham
9/1/2021	$75.00 → $95.00	Buy	HC Wainwright & Co.